You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Claims for Patent: 9,186,346

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,186,346

Title:	Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
Abstract:	This invention relates to a method for managing the risk of an adverse interaction between teriflunomide and a substrate of breast cancer resistance protein (BCRP) and/or organic anion transporting polypeptide B1 and B3 (OATP1B1/B3).
Inventor(s):	Weitz; Dietmar (Konigstein im Taunus, DE), Menguy-Vacheron; Francoise (Paris, FR), Clot; Pierre-Francois (Epinay sur Orge, FR), Turpault; Sandrine (Pennington, NJ)
Assignee:	SANOFI (Paris, FR)
Application Number:	14/172,082
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,186,346
Patent Claims:	1. A method for treating multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction in a patient having multiple sclerosis, wherein rosuvastatin is co-administered with teriflunomide, comprising administering to the patient about 7 or 14 mg of teriflunomide daily, and administering to the patient rosuvastatin which is at the amount of about 50% of the normal dose of rosuvastatin. 2. The method according to claim 1, wherein the patient has relapsing forms of multiple sclerosis. 3. The method according to claim 1, wherein rosuvastatin is co-administered with teriflunomide at the same time. 4. The method according to claim 2, wherein rosuvastatin is co-administered with teriflunomide at the same time. 5. A method for treating multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction in a patient having multiple sclerosis, wherein rosuvastatin is co-administered with teriflunomide, comprising administering to the patient about 7 or 14 mg of teriflunomide daily, and administering to the patient rosuvastatin at a dose that does not exceed 10 mg once daily. 6. The method according to claim 5, wherein the patient has relapsing forms of multiple sclerosis. 7. The method according to claim 5, wherein rosuvastatin is co-administered with teriflunomide at the same time. 8. The method according to claim 6, wherein rosuvastatin is co-administered with teriflunomide at the same time.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.